065660.KQ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2024 @ 08:30):
Our systems believe the stock currently is undervalued by 0.72% compare to its pairs and should correct upwards.

Stats
Dagens volum	6 699
Gjennomsnittsvolum	49 377
Markedsverdi	141.59B
EPS	KRW-58.72 ( Q1 \| 2024-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW35.16 (0.24%)

Korrelasjon (AI algo v.1.1b): Undervalued: 0.72% KRW14 755 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: -0.49 (neutral)

Signal:(56.101) Neutral

Anterogen.Co.,Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Anterogen.Co.,Ltd. Korrelasjon - Valuta/Råvare

0.03
( neutral )

0.02
( neutral )

0.32
( neutral )

0.26
( neutral )

-0.13
( neutral )

-0.15
( neutral )

Anterogen.Co.,Ltd. Økonomi

Annual	2023
Omsetning:	KRW6.50B
Bruttogevinst:	KRW2.21B (34.05 %)
EPS:	KRW-291.93

FY	2023
Omsetning:	KRW6.50B
Bruttogevinst:	KRW2.21B (34.05 %)
EPS:	KRW-291.93

FY	2022
Omsetning:	KRW6.59B
Bruttogevinst:	KRW2.62B (39.70 %)
EPS:	KRW-705.88

Financial Reports:

No articles found.

Anterogen.Co.,Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.